Allos Therapeutics Inc.'s stock soared 61.5 percent Thursday after the company said it would file a new drug application for a synthetic small molecule shown to double median survival time in breast cancer patients. (BioWorld Today)

Allos Therapeutics Inc.'s stock soared 61.5 percent Thursday after the company said it would file a new drug application for a synthetic small molecule shown to double median survival time in breast cancer patients. (BioWorld Today)

WASHINGTON - Companies required to conduct postmarketing studies should expect to find themselves under closer scrutiny by the FDA and the public as the government begins tracking progress on such trials in the Federal Register. (BioWorld Today)

WASHINGTON - Companies required to conduct postmarketing studies should expect to find themselves under closer scrutiny by the FDA and the public as the government begins tracking progress on such trials in the Federal Register. (BioWorld Today)